Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease?

International Journal of Urology

Volumn 18, Issue 11, 2011, Pages 796-800

  Nam, Hyung Jong ^a   Park, Hyun Jun ^a,b   Park, Nam Cheol ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Deficiency; Hypogonadism; Peyronie's disease; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; ANDROGEN DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; PAINFUL ERECTION; PENIS CURVATURE; PENIS DISEASE; PENIS PLAQUE SIZE; PEYRONIE DISEASE; PRIORITY JOURNAL; SMOKING; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL SYSTEM PARAMETERS;

AGED; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PENILE INDURATION; PENIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TESTOSTERONE;

EID: 80355142018     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02842.x     Document Type: Article

References (31)

1. Mulhall JP. Expanding the paradigm for plaque development in Peyronie's disease. Int. J. Impot. Res. 2003; 15 (Suppl 5): S93-102.
2. Pryor J, Akkus E, Alter G etal. Peyronie's disease. J. Sex. Med. 2004; 1: 110-15.
3. Mulhall JP, Creech SD, Boorjian SA etal. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J. Urol. 2004; 171: 2350-3.
4. Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int. J. Impot. Res. 2004; 16: 540-3.
5. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001; 88: 727-30.
6. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J. Sex. Med. 2009; 6: 1729-35.
7. Engeland CG, Sabzehei B, Marucha PT. Sex hormones and mucosal wound healing. Brain Behav. Immun. 2009; 23: 629-35.
8. Petroianu A, Veloso DF, Alberti LR, Figueiredo JA, Rodrigues FH, Carneiro BG. Hypoandrogenism related to early skin wound healing resistance in rats. Andrologia 2010; 42: 117-20.
9. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
10. Wang C, Nieschlag E, Swerdloff R etal. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J. Androl. 2009; 30: 1-9.
11. Park NC. A manual of 2008 ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Korean J Androl. 2009; 27: 63-73.
12. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J. Urol. 2002; 168: 621-5.
13. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie's disease. Int. J. Impot. Res. 2002; 14: 361-74.
14. Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J. Cell. Physiol. 1998; 175: 184-92.
15. Burnett AL. Nitric oxide in the penis: physiology and pathology. J. Urol. 1997; 157: 320-4.
16. Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol. Reprod. 1992; 46: 342-8.
17. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J. Androl. 1997; 18: 110-15.
18. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995; 136: 1495-501.
19. Syme DB, Corcoran NM, Bouchier-Hayes DM, Morrison WA, Costello AJ. The effect of androgen status on the structural and functional success of cavernous nerve grafting in an experimental rat model. J. Urol. 2007; 177: 390-4.
20. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int. J. Impot. Res. 1995; 7: 209-19.
21. Valente EG, Vernet D, Ferrini MG, Qian A, Rajner J, Gonzalez-Cadavid NF. l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-44.
22. Vernet D, Ferrini MG, Valente EG etal. Effect of nitric oxide on the differentiation of fibroblast into myofibroblast in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002; 7: 262-76.
23. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail. Rev. 2004; 9: 53-61.
24. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J. Sex. Med. 2011; 8: 1472-7.
25. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 2006; 97: 625-33.
26. Kovanecz I, Rambhatla A, Ferrini MG etal. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008; 101: 203-10.
27. Demling RH. The role of anabolic hormones for wound healing in catabolic states. J. Burns Wounds 2005; 4: e2.
28. Rhoden EL, Riedner CE, Fuchs SC, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. J. Sex. Med. 2010; 7: 1529-37.
29. El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur. Urol. 2006; 49: 564-9.
30. Morgentaler A. Testosterone and sexual function. Med. Clin. North Am. 2006; 90: 32-4.
31. Rhoden EL, Buselato LG, Ting HY, Teloken C, Souto CA. Is there any association between Peyronie's disease and serum collagen markers? Int. J. Impot. Res. 2002; 12: 302-4.